bluuebunny/crossref_metadata_2025_split huggingface dataset:
Immunoexpression of p16 in uterine leiomyomas with infarct‐type necrosis: an analysis of 35 cases
Authors: Ip Philip P , Lim Diana , Cheung Annie N Y , Oliva Esther 
Published: June 2017

AimsUterine leiomyosarcomas frequently show p16 immunoexpression. However, p16 may also be expressed in some benign leiomyoma variants such as leiomyomas with bizarre nuclei and cellular leiomyomas, limiting its utility as a biomarker to distinguish between benign and malignant neoplasms. We investigated p16 expression in leiomyomas with infarct‐type necrosis, tumours which may sometimes be misinterpreted as smooth muscle tumours of uncertain malignant potential or even leiomyosarcoma on conventional light microscopy.Methods and resultsp16 immunostaining was performed on 35 leiomyomas with infarct‐type necrosis and the staining pattern was analysed. Staining was classified as absent, scattered/isolated, <33‐, 33–66‐ or >66%‐positive cells, and was assessed in the areas immediately surrounding and distant from the infarct. The median age of patients was 44 years. Seventeen had hormonal/non‐hormonal drugs and three were pregnant. The median tumour size was 7.25 cm. The mean mitotic count was 0.9/10 high‐power fields. Only one tumour had multifocal mild nuclear atypia. Positive p16 was noted in 34 of 35 (97.2%) tumours. It was typically patchy, and was concentrated in areas immediately surrounding the necrosis. Distant from the necrosis, p16 positivity was seen predominantly in scattered/isolated cells. One tumour without any worrisome microscopic features showed diffuse p16 positivity throughout. Median follow‐up was 55 months, and none of the patients experienced any recurrence.Conclusionp16 expression in benign uterine smooth muscle tumours with infarct‐type necrosis is common. The staining is particularly concentrated adjacent to areas of necrosis. It is important to be aware of this potential pitfall when interpreting p16 expression.
Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry
Authors: Almeida Antonio M. , Bedrosian Camille , Cole Alexander , Muus Petra , Schrezenmeier Hubert , Szer Jeff , Rosse Wendell F. 
Published: June 2017

AbstractBackgroundEculizumab reduces intravascular haemolysis and improves disease symptoms in patients with paroxysmal nocturnal haemoglobinuria (PNH).AimsTo characterise, in a real‐world setting, the effect of eculizumab in patients with haemolytic PNH (lactase dehydrogenase (LDH) ≥ 1.5 upper limit of normal) and no history of red blood cell transfusion, including those with high disease activity (HDA).MethodsThree populations from the International PNH Registry were studied: (i) non‐transfused, untreated; (ii) non‐transfused, eculizumab‐treated and (iii) transfused, eculizumab‐treated (≥1 transfusions in 6 months prior to eculizumab initiation). Using multivariate linear regression, the primary outcome was mean absolute change from baseline to 6 months in LDH (U/L) in non‐transfused patients who were treated with eculizumab versus those who remained untreated. Secondary outcomes were mean changes in functional assessment of chronic illness therapy (FACIT)‐Fatigue and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC‐QLQ)‐C30 Fatigue scores from baseline to last available assessment.ResultsThe study population included (i) 144 non‐transfused, untreated patients; (ii) 45 non‐transfused, eculizumab‐treated patients and (iii) 105 transfused, eculizumab‐treated patients. Of these, 136/144, 43/45 and 99/105 had HDA respectively. Compared with untreated patients, non‐transfused, treated patients had greater absolute reduction in LDH (−1318.8 vs −39.4; P < 0.001) and greater percentage reduction in LDH (−69.9 vs −1.6%; P < 0.001). Clinically meaningful improvements in FACIT‐Fatigue (73.7 vs 24.6%, respectively) and in EORTC‐QLQ‐C30 (84.2 vs 33.3%, respectively) were observed. Non‐transfused, treated patients with HDA had significantly reduced LDH levels (P < 0.001) and clinically meaningful improvements in FACIT‐Fatigue (P = 0.003) and EORTC‐QLQ‐C30 (P = 0.020) versus untreated patients.ConclusionSignificant LDH reduction and clinically meaningful improvement in fatigue were observed in patients with PNH and HDA treated with eculizumab versus untreated patients, irrespective of transfusion history.
Book Reviews
Authors: Affleck Gordon Burt 
Published: June 2017

COMMERCIAL ARBITRATION BY MARTIN DOMKE (Englewood Cliffs, N.J.: Prentice‐Hall, Inc., 1965. 116 pages. $2.25, paperbound)RESOLVING BUSINESS DISPUTES: THE POTENTIAL OF COMMERCIAL ARBITRATION (New York: American Management Association, Inc., 1965. 208 pages. $6.00, members; $9.00, nonmembers)
Purchasing Performance: What Makes the Magic?
Authors: Cavinato Joseph L. 
Published: June 2017

Traditional formal reporting systems do not always do the job in effectively communicating purchasing's accomplishments. Nor are these cold, hard numbers effective in elevating the views non‐purchasing managers have of this key function.In‐depth interviews with CEOs and major department heads in more than fifty companies, and surveys of their counterparts in nearly two hundred other firms, revealed that purchasing's performance is often assessed under a broader umbrella of evaluative factors. This article discusses the five key factors that others typically use when viewing and evaluating their company's purchasing operation.
Sourcing from Less Developed Countries: A Case Study
Authors: Caddick J.R. , Dale B.G. 
Published: June 2017

This article reports the results of a study conducted in a European subsidiary of an American‐based firm. The research focuses on the development of a formal approach to international sourcing, with an emphasis on the less developed countries.Results indicate that decision making in sourcing from less developed countries is considerably more complex than it is in the domestic market. There are more variables in the decision matrix; a greater need exists to understand the macro‐economies of the sourcing countries; and more evaluative risk taking is involved in the decision‐making process. This requires the accumulation and interpretation of much more information than is the case in domestic sourcing.
Demand Variability and Cost Effectiveness of the Incremental Part‐Period Algorithm
Authors: Jordan Paul C. 
Published: June 2017

Recent studies have suggested that increased variability of demand (lumpyness) increases the total variable cost of the optimal schedules for various dynamic lot‐sizing algorithms. These investigations, however, have had a relatively small number of schedules, and researchers have only suggested that this effect may be true.This research looks at the effect of variability on 1,600 distinct combinations of demand level and variability. For each combination, 100 random normal demand patterns are evaluated. The average TVC for each 100 schedules is calculated, and computer graphics are used to show the relationships.
Implementing Electronic Data Interchange
Authors: Monczka Robert M. , Carter Joseph R. 
Published: June 2017

Electronic data interchange (EDI) is the direct electronic transmission, computer to computer, of standard business forms between two organizations/In the purchasing environment, documents are transmitted “over the wire,” eliminating the need to generate hard copies and to distribute them manually. By utilizing EDI in purchasing, a buyer and a supplier are operating in a near ‘real‐time’ environment, which can reduce incoming material delays by shortening procurement lead times.This article is the second of two reports that present the results of a major research project, funded by the Computer Information Systems and Technology Group of the National Association of Purchasing Management and Michigan State University, that focused on the implementation of electronic data interchange in a purchasing environment. The article presents a framework that can help managers find patterns and trends in the EDI system design and installation process in order to develop a useful model for EDI implementation in their firms.
The Supplier Selection Decision in Strategic Partnerships
Authors: Ellram Lisa M. 
Published: June 2017

The concept of partnerships between buyers and suppliers is receiving increasing attention in American industry. This article examines the issue of supplier selection in situations where the firm is considering a partnership type of relationship with potential suppliers. The argument is made that partnerships are different in nature than traditional buyer‐supplier relationships, and thus require the consideration of additional factors in supplier selection.This study combines a literature review with the use of case studies of firms involved in buyer‐supplier partnerships to develop additional factors that should be considered in the selection of supply partners. Four categories of additional factors are developed: (1) financial issues, (2) organizational culture and strategy, (3) technology, and (4) a group of miscellaneous factors. The issues included in these categories tend to be longer term and more qualitative than factors included in traditional supplier selection models.The article suggests that these additional factors supplement, rather than replace, the more traditional factors in developing strategic partnerships with suppliers.
Technology Management: An Important Element in the Supplier Capability Survey
Authors: Presutti William D. 
Published: June 2017

Technology management has become an important issue as the United States wrestles with ways to remain competitive in an ever‐aggressive global marketplace. It is becoming increasingly clear that investment in new technology is not enough to establish that competitiveness. How effectively firms manage the internal use of their manufacturing technologies is also of fundamental importance.Purchasing professionals can contribute to the nation's efforts to improve the management of its capital stock by including technology management as part of the supplier capability survey. This requires careful evaluation of how suppliers manage certain key activities in their operations that have an impact on the quality of their technology management efforts. A recent survey among purchasing professionals suggests a degree of unevenness in purchasing's evaluation of those key activities.
Operationalizing Quality Considerations in the Purchasing Proces
Authors: Perry James H. , Perkins Charles A. 
Published: June 2017

This article examines the use of product quality information in capital equipment purchasing decisions. The authors incorporate specific quality factors in a simple analytical model designed to provide a buyer with the capability to appropriately consider quality differences in reaching a cost‐effective purchasing decision.Initially, dimensions of product quality are identified and discussed based on the parameters proposed by David Garvin. Using the Garvin framework, the article then reports the results of a study of procurement professionals in which the feasibility and desirability of explicit consideration of quality factors in the purchasing process are established. Finally, the article extends the consideration of specific quality factors by introducing and illustrating an analytical approach that effectively incorporates quality differences in a structured and auditable model. The model projects the cost implications to the firm of those quality differences identified. The analysis indicates that generally accepted dimensions of quality can be identified and applied operationally to assist a buyer in making the most effective purchasing decision.
Using the Analytic Hierarchy Process to Structure the Supplier Selection Procedure
Authors: Nydick Robert L. , Hill Ronald Paul 
Published: June 2017

The supplier selection problem is perhaps the most important component of the purchasing function. Some of the common and influential criteria in the selection of a supplier include quality, price, delivery, and service. These evaluation criteria often conflict, however, and it is frequently impossible to find a supplier that excels in all areas. In addition, some of the criteria are quantitative and some are qualitative. Thus, a methodology is needed that can capture both subjective and objective evaluation measures.The Analytic Hierarchy Process (AHP) is a decision‐making method for ranking alternative courses of action when multiple criteria must be considered. This article shows how AHP can be used to structure the supplier selection process. This method of selection is described, and a detailed, hypothetical example of how AHP can be used also is provided. Finally, a framework is presented that any buying organization can adapt to fit its specific set of needs.
What's normal anyway? Residual plots are more telling than significance tests when checking ANOVA assumptions
Authors: Kozak M. , Piepho H.‐P. 
Published: June 2017

AbstractWe consider two questions important for applying analysis of variance (ANOVA): Should normality be checked on the raw data or on the residuals (or is it immaterial which of the two approaches we take)? Should normality and homogeneity of variance be checked using significance tests or diagnostic plots (or both)? Based on two examples, we show that residuals should be used for model checking and that residual plots are better for checking ANOVA assumptions than statistical tests. We also discuss why one should be very cautious when using statistical tests to check the assumptions.
Hydrogen Sulphide modulating mitochondrial morphology to promote mitophagy in endothelial cells under high‐glucose and high‐palmitate
Authors: Liu Ning , Wu Jichao , Zhang Linxue , Gao Zhaopeng , Sun Yu , Yu Miao , Zhao Yajun , Dong Shiyun , Lu Fanghao , Zhang Weihua 
Published: June 2017

AbstractEndothelial cell dysfunction is one of the main reasons for type II diabetes vascular complications. Hydrogen sulphide (H2S) has antioxidative effect, but its regulation on mitochondrial dynamics and mitophagy in aortic endothelial cells under hyperglycaemia and hyperlipidaemia is unclear. Rat aortic endothelial cells (RAECs) were treated with 40 mM glucose and 200 μM palmitate to imitate endothelium under hyperglycaemia and hyperlipidaemia, and 100 μM NaHS was used as an exogenous H2S donor. Firstly, we demonstrated that high glucose and palmitate decreased H2S production and CSE expression in RAECs. Then, the antioxidative effect of H2S was proved in RAECs under high glucose and palmitate to reduce mitochondrial ROS level. We also showed that exogenous H2S inhibited mitochondrial apoptosis in RAECs under high glucose and palmitate. Using Mito Tracker and transmission electron microscopy assay, we revealed that exogenous H2S decreased mitochondrial fragments and significantly reduced the expression of p‐Drp‐1/Drp‐1 and Fis1 compared to high‐glucose and high‐palmitate group, whereas it increased mitophagy by transmission electron microscopy assay. We demonstrated that exogenous H2S facilitated Parkin recruited by PINK1 by immunoprecipitation and immunostaining assays and then ubiquitylated mitofusin 2 (Mfn2), which illuminated the mechanism of exogenous H2S on mitophagy. Parkin siRNA suppressed the expression of Mfn2, Nix and LC3B, which revealed that it eliminated mitophagy. In summary, exogenous H2S could protect RAECs against apoptosis under high glucose and palmitate by suppressing oxidative stress, decreasing mitochondrial fragments and promoting mitophagy. Based on these results, we proposed a new mechanism of H2S on protecting endothelium, which might provide a new strategy for type II diabetes vascular complication.
Folic acid reduces doxorubicin‐induced cardiomyopathy by modulating endothelial nitric oxide synthase
Authors: Octavia Yanti , Kararigas Georgios , de Boer Martine , Chrifi Ihsan , Kietadisorn Rinrada , Swinnen Melissa , Duimel Hans , Verheyen Fons K. , Brandt Maarten M. , Fliegner Daniela , Cheng Caroline , Janssens Stefan , Duncker Dirk J. , Moens An L. 
Published: June 2017

AbstractThe use of doxorubicin (DOXO) as a chemotherapeutic drug has been hampered by cardiotoxicity leading to cardiomyopathy and heart failure. Folic acid (FA) is a modulator of endothelial nitric oxide (NO) synthase (eNOS), which in turn is an important player in diseases associated with NO insufficiency or NOS dysregulation, such as pressure overload and myocardial infarction. However, the role of FA in DOXO‐induced cardiomyopathy is poorly understood. The aim of this study was to test the hypothesis that FA prevents DOXO‐induced cardiomyopathy by modulating eNOS and mitochondrial structure and function. Male C57BL/6 mice were randomized to a single dose of DOXO (20 mg/kg intraperitoneal) or sham. FA supplementation (10 mg/day per oral) was started 7 days before DOXO injection and continued thereafter. DOXO resulted in 70% mortality after 10 days, with the surviving mice demonstrating a 30% reduction in stroke volume compared with sham groups. Pre‐treatment with FA reduced mortality to 45% and improved stroke volume (both P < 0.05 versus DOXO). These effects of FA were underlain by blunting of DOXO‐induced cardiomyocyte atrophy, apoptosis, interstitial fibrosis and impairment of mitochondrial function. Mechanistically, pre‐treatment with FA prevented DOXO‐induced increases in superoxide anion production by reducing the eNOS monomer:dimer ratio and eNOS S‐glutathionylation, and attenuated DOXO‐induced decreases in superoxide dismutase, eNOS phosphorylation and NO production. Enhancing eNOS function by restoring its coupling and subsequently reducing oxidative stress with FA may be a novel therapeutic approach to attenuate DOXO‐induced cardiomyopathy.
Factors associated with the choice of the first biologic in psoriasis: real‐life analysis from the Psobioteq cohort
Authors: Sbidian E. , Giboin C. , Bachelez H. , Paul C. , Beylot‐Barry M. , Dupuy A. , Viguier M. , Lacour J.‐P. , Schmutz J.‐L. , Bravard P. , Mahé E. , Beneton N. , Misery L. , Delaporte E. , Modiano P. , Barbarot S. , Regnier E. , Jullien D. , Richard M.‐A. , Joly P. , Tubach F. , Chosidow O. 
Published: June 2017

AbstractBackgroundDecision‐making is a complex process. The aim of our study was to assess factors associated with the choice of the first biological treatment in patients with moderate‐to‐severe psoriasis.MethodsData on all patients included in the French prospective, observational, cohort, Psobioteq and initiating a first biologic prescription between July 2012 and July 2016 were analysed. Demographic information and clinical features were collected during routine clinical assessments by the dermatology team at the recruiting centres using a standardized case report form. The primary outcome was the nature of the first biologic treatment. Four groups were identified as follows: adalimumab, etanercept, ustekinumab and infliximab groups. Factors associated with the choice of the first biological agent were determined by a multinomial logistic regression model adjusted on year of inclusion.ResultsThe study population included the 830 biological‐naïve patients who initiated a first biological agent. The mean age was 46.6 years (±SD 13.9), and 318 patients (38.3%) were female. The most commonly prescribed biologic was adalimumab: 355 (42.8%) patients, then etanercept (n = 247, 29.8%), ustekinumab (n = 194, 23.4%) and infliximab (n = 34, 4.0%). In the multinomial logistic regression analysis, patients were significantly more likely to receive adalimumab if they had a severe psoriasis as defined by baseline PASI or if they had psoriatic arthritis compared to etanercept (aOR, 0.42; 95% CI, 0.16–1.07) and ustekinumab (aOR, 0.15; 95% CI, 0.04–0.52). Patients were significantly more likely to receive ustekinumab (aOR, 2.39; 95% CI, 1.04–5.50) if they had a positive screening for latent tuberculosis compared to adalimumab. Younger patients were also more likely to receive ustekinumab. Patients with chronic obstructive pulmonary disease were more likely to be prescribed ustekinumab or etanercept compared to adalimumab. There was a trend in favour of etanercept prescription in patients with cardiovascular comorbidities, metabolic syndrome and in patients with a history of cancer.ConclusionWe identified patient‐ and disease‐related factors that have important influence on the choice of the first biological agent in clinical practice. Clinicians appear to have a holistic approach to patient characteristics when choosing a biological agent in psoriasis.
Ecological drivers of body size evolution and sexual size dimorphism in short‐horned grasshoppers (Orthoptera: Acrididae)
Authors: García‐Navas V. , Noguerales V. , Cordero P. J. , Ortego J. 
Published: June 2017

AbstractSexual size dimorphism (SSD) is widespread and variable in nature. Although female‐biasedSSDpredominates among insects, the proximate ecological and evolutionary factors promoting this phenomenon remain largely unstudied. Here, we employ modern phylogenetic comparative methods on eight subfamilies of Iberian grasshoppers (85 species) to examine the validity of different models of evolution of body size andSSDand explore how they are shaped by a suite of ecological variables (habitat specialization, substrate use, altitude) and/or constrained by different evolutionary pressures (female fecundity, strength of sexual selection, length of the breeding season). Body size disparity primarily accumulated late in the history of the group and did not follow a Brownian motion pattern, indicating the existence of directional evolution for this trait. We found support for the converse of Rensch's rule (i.e. females are proportionally bigger than males in large species) across all taxa but not within the two most speciose subfamilies (Gomphocerinae and Oedipodinae), which showed an isometric pattern. Our results do not provide support for the fecundity or sexual selection hypotheses, and we did not find evidence for significant effects of habitat use. Contrary to that expected, we found that species with narrower reproductive window are less dimorphic in size than those that exhibit a longer breeding cycle, suggesting that male protandry cannot solely account for the evolution of female‐biasedSSDin Orthoptera. Our study highlights the need to consider alternatives to the classical evolutionary hypotheses when trying to explain why in certain insect groups males remain small.
Remote control improves quality of life in elderly pacemaker patients versus standard ambulatory‐based follow‐up
Authors: Comoretto Rosanna Irene , Facchin Domenico , Ghidina Marco , Proclemer Alessandro , Gregori Dario 
Published: June 2017

AbstractBackgroundHealth‐related quality of life (HRQoL) improves shortly after pacemaker (PM) implantation. No studies have investigated the HRQoL trend for elderly patients with a remote device monitoring follow‐up system.MethodsUsing EuroQol‐5D Questionnaire and the PM‐specific Assessment of Quality of Life and Related Events Questionnaire, HRQoL was measured at baseline and then repeatedly during the 6 months following PM implantation in a cohort of 42 consecutive patients. Twenty‐five patients were followed‐up with standard outpatient visits, while 17 used a remote monitoring system.ResultsAquarel scores were significantly higher in patients with remote device monitoring system regarding chest discomfort and arrhythmia subscales the first month after PM implant and remained stable until 6 months. Remote monitoring affected the rate of HRQoL improvement in the first 3 months after pacemaker implantation more than ambulatory follow‐up.ConclusionsRemote device monitoring has a significant impact on HRQoL in pacemaker patients, increasing its levels up to 6 months after implant.